Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Collaborates with Axon on Cell-Manipulation Microfluidic Chip Platform


Microfluidics maker Fluidigm has signed a collaboration with Axon Instruments to develop a cell capture and manipulation microfluidics chip for drug discovery, the company said.

Under the agreement, Fluidigm, of South San Francisco, Calif., will use its flexible rubber microfluidics technology to design the chip to Axon''s specifications, and Axon will design an instrument platform for using the chips, which will be disposable. Axon will likely market the device and the chips, said Rodney Turner, Fluidigm''s vice president of business development.

The companies have conceptualized this microfluidics platform as a new tool for precisely handling and manipulating tiny amounts of eukaryotic cells. They expect the system to be used by researchers to study drug target function in a natural cellular environment.

"This is one of Axon''s strategic efforts to access the drug discovery space," said Turner. "The deal we have with them plays to their ambition and strategy in instrument development for high-throughput screening."

Fluidigm''s chips contain microscopic valves and pumps that can be activated through application of precise amounts of air pressure.

Turner said Fluidigm would be announcing another collaboration shortly.



The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.